Introduction
============

Translation the process by which mRNAs are translated into proteins by ribosomes. Eukaryotic ribosomes are evolutionarily conserved ribozymes constituted by ribosomal proteins (RPs) and rRNAs, whose structure has been spectacularly resolved ([@B7]; [@B48]; [@B47]). Ribosome biogenesis is a massive process occurring in the nucleolus of all cells. Recent progress, combining biochemical techniques, with structural and genetic evidence, has shown that ribosome synthesis is catalyzed and coordinated by more than 200 biogenesis factors. Ribosome biogenesis, therefore, proceeds through precise assembly steps that include several quality checkpoints, both in the nucleus and in the cytoplasm ([@B50]; [@B73]). Furthermore, impairment of these checkpoints leads to defects in maturation that are associated with disease ([@B70]; [@B81]).

In the cytoplasm, ribosomes are thought to constitute the hardware of the protein synthesis machinery, which fulfills its activity through four main phases: initiation, elongation, termination, and recycling. The initiation step is one of the most important steps of translation regulation, involving initiation factors, mRNAs, tRNAs, and ribosomes. Briefly, 40S subunits directly bind mRNAs in a way that is dependent on initiation factors and on mRNA structure and, after mRNA binding and scanning to an appropriate start codon, 60S subunits are recruited. Several studies elucidated how translation initiation is affected by alteration in mRNAs-binding factors ([@B59]; [@B17]; [@B100]) and by different features in mRNAs structures, i.e., Untranslated regions (UTRs). Recently, also tRNA has been linked to selective translation, and reprogramming of metabolism since codon reprogramming leads to HIF1α synthesis and an increase of glycolytic factors ([@B75]).

Evidences that ribosomes exist in different forms in different cell types or during different stages of development ([@B66]; [@B10]; [@B104]) have suggested the presence of ribosome heterogeneity. It has been recently demonstrated that mutations in some RPs result in selective translation ([@B85]) and mutations in proteins causing an impairing in ribosome maturation and function, as in the case of ribosomopathies, show a specific mRNA translation signature ([@B11]; [@B44]) In conclusion, in recent years there has been growing evidence that translation is driven by ribosome heterogeneity, manifested as ribosome populations differing in ribosomal components. In this review we discuss ribosome heterogeneity in physiological, and pathological conditions, highlighting the role of translation machinery in driving the last step of the molecular biology central dogma, which elects ribosomes as players in specific mRNAs translation.

Ribosome Heterogeneity in Physiological Conditions May Account for Differential Translation
-------------------------------------------------------------------------------------------

This topic has been recently discussed ([@B35],[@B36]) and we will give a simple summary of some perspectives. Ribosomes are constituted by approximately 80 RPs. For many years now, it is known that the relative abundance of different RPs, in different tissues, or in different growth conditions, may vary ([@B66]; [@B10]; [@B104]). This is a *sine qua non*-condition for ribosomal heterogeneity. An obvious alternative explanation for an imbalance of the stoichiometry of RPs within a cell is that RPs perform ribosome-independent functions. An experimental complexity is, therefore, to define whether a differential translation is due to the direct action of heterogeneous ribosomes or to regulatory pathways affected by free RPs. This is the case for RACK1 that was originally isolated as a PKC receptor ([@B79]; [@B32]). RACK1 is a structural protein of 40S subunits ([@B37]), involved in several extraribosomal functions ([@B60]; [@B78]; [@B107]; [@B33]; [@B30]). RACK1 may affect the efficiency of ribosomes directly ([@B14]; [@B87]; [@B38]; [@B24],[@B25]) or indirectly through signaling pathways ([@B33]; [@B105]). In conclusion, data demonstrate that in physiological conditions, ribosomal networks may be more complex than expected and perform choices in translational regulation.

Ribosomal heterogeneity exists in physiological conditions. Accurate proteomics studies have identified sub-stoichiometric relationships within translating polysomes ([@B86]), showing that ribosomes may preferentially translate specific mRNAs. An experimental validation shows that ribosomes devoid of either RPS25 (eS25) or RpL10A (uL1), *in vivo*, translate specific mRNAs. Mechanistically, this study shows that the 60S subunits may affect mRNA recruitment through the binding of RPL10A (uL1) to IRES (Internal Ribosome Entry Site) sequences in the 5^′^UTR ([@B86]). In monocytes, interferon gamma driven phosphorylation results in RPL13A (uL13) detachment, but here it is still unknown whether ribosomes devoid of RPL13A (uL13) are able to translate selectively ([@B45]). Furthermore, RPL10 (uL16) R98S mutant leukemia cells are able to survive high oxidative stress levels by increasing IRES-dependent BCL-2 translation ([@B46]).

Thus, the concept of a monolithic ribosome ([@B68]; [@B116]) may be accompanied by the existence of a more flexible ribosomal platform that performs further tuning on gene expression ([@B85]).

Ribosome Heterogeneity in Pathological Conditions Affects Translation and Gene Expression
-----------------------------------------------------------------------------------------

Ribosomopathies are inherited diseases caused by the loss of ribosomal component functionality. Some examples of ribosomopathies include Diamond-Blackfan Anemia syndrome (DBA), Shwachman-Diamond syndrome (SDS), Treacher Collins syndrome, 5q-myelodysplastic syndrome, and Dyskeratosis Congenita (DKC). Notably, all of these syndromes are characterized by variably penetrant phenotypes in which specific tissue deficits are found ([@B70]). Early on, it was shown that DKC1 mutations reduce pseudouridylation and impair IRES mediated translation ([@B114]).

As a case for study, we will focus our discussion on SDS. Signs of SDS include a peculiar exocrine pancreatic insufficiency, along with neutropenia and variable abnormalities in the skeleton and other organs. In addition, SDS is characterized by a reduction in growth, accompanied by an increased incidence of Acute Myeloid Leukemia, (AML; [@B26]). At the ribosomal level, SDS is characterized by the partial loss of free 60S ribosomal subunits due to, in most cases, mutations in the *SBDS* gene that is necessary for 60S maturation ([@B9]; [@B110]). In a minority of cases, mutations of *EFL1p*, which acts in synergy with *SBDS*, have been found ([@B91]; [@B95]). Overall, the reduced functionality of 60S ribosomes is a common theme for SDS ([@B106]). All together these findings generate three questions: (a) how the loss of functionality of ubiquitous 60S ribosomes can generate tissue-specific defects, (b) how specific translational programs can be affected by the lack of 60S subunits, (c) how can we reconcile increased tumor with reduced growth.

Addressing this last question helps to put in the right context the other two. We have recently demonstrated in our lab that cells with mutant *Sbds* have reduced colony formation ability and are transformed less efficiently by oncogenes ([@B12]). In this context, we demonstrated that *Sbds* deficiency directly acts by reducing the maximal oncogenic and translational capability of cells ([@B12]). The paradox of reduced growth associated with tumor predisposition may not necessarily be associated with specific translation in tumor cells, but with a general impairment of tissue homeostasis that favors the appearance of mutant clones. For instance, increased tumor formation is observed in immunocompromised individuals ([@B102]). To support this interpretation, the relationship between neutropenia and AML was described by different groups ([@B31]; [@B56]; [@B98]). In conclusion, different cell types can be differentially affected by the reduction of RPs, i.e., thresholds can be different depending on the specific cellular demand of ribosomes for translation.

The question of the mechanism by which defects in 60S ribosomes lead to differential translation is more challenging since to our knowledge mRNA selection is driven by 40S subunits, prior to 60S engagement. However, the effects of 60S levels on specific translation are pervasive, and, as described before, IRES mRNA binding can be affected by RPL10 (uL16). In the case of *Sbds* depletion, characterized by reduced free 60S, two studies have addressed the question of preferential translation performing either microarray ([@B71]), or RNA-Seq on polysomes ([@B12]). In addition, a reporter-based study has addressed the effect of *SBDS* depletion on reinitiation ([@B44]). Together, these studies support a model in which the SBDS deficiency reduces free 60S levels diminishing the maximal translational capability, and simultaneously changing translational selectivity. In this context, mRNAs that are intrinsically poorly translated because of uORFs (upstream Open Reading Frames) that require reinitiation are particularly disfavored. Similarly, mouse models have underscored that the reduction of 60S RPs affects the translational program of IRES containing mRNAs ([@B6]; [@B49]; [@B111]).

Finally, mathematical modeling of translation suggests that a quantitative reduction in the translational output may result in strong alterations of specific mRNA translation due to stochastic events ([@B42]; [@B65]). We conclude that some mRNAs can be particularly sensitive to ribosomal availability, and we speculate that this property has been evolutionarily exploited to connect ribosomes with other cellular events. What we still lack is understanding the precise mechanisms.

A Common Theme for the Regulatory Function of Ribosomes?
--------------------------------------------------------

Metabolic pathways are necessary for converting essential nutrients into energy and macromolecules that sustain cell growth and proliferation. Nutrients and metabolic pathways control all facets of cellular functions. Nutrient and growth factors converge on the translational machinery through signaling pathways that, in turn, regulate the synthesis of ribosomes and the activity of translation factors ([@B80]). Then, translation factors crosstalk to metabolic choices ([@B8]). Some well-established observations are the following. mTORC1 controls mitochondrial activity and biogenesis by selectively promoting translation of nucleus-encoded mitochondria-related mRNAs, via inhibition of the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs; [@B69]). ROS generation is also controlled partly at the translational level through eIF4E ([@B99]). Glutamine metabolism is controlled by eIF4B-mediated translation downstream of mTORC1 pathway ([@B18]). eIF3 complex mediates energy metabolism ([@B84]). Rate-limiting initiation factors that link 60S ribosome biogenesis to translation as eIF6 hierarchically control lipid synthesis and metabolism, through uORF and G/C rich 5^′^UTR sequences ([@B11]). eIF5A2 accelerates lipogenesis in hepatocellular carcinoma ([@B13]). In general, translation and metabolism are dysregulated in a coordinated fashion ([@B53]), and initiation factors may act upstream of metabolic reprogramming ([@B8]). The next question is whether ribosomes also control metabolic pathways.

In Zebrafish, *rpl11* mutation decreased the glycolytic rate and the lower activity of glycolytic enzymes is rescued by p53 inhibition ([@B21]). Moreover, defects, mutations or imbalance of RPs stabilized p53 and changed metabolic flux, specifically by decreasing glycolysis and enhancing aerobic respiration ([@B23]). Albeit these data do not support a direct crosstalk between ribosome activity and metabolism, they suggest overall that when the translation machinery is perturbed, coordinated pathways involved in cell homeostasis and metabolism are also altered.

Recently, it has been shown that SDS cells display an impairment in Complex IV activity, which causes an oxidative phosphorylation metabolic defect, with a consequent decrease in ATP production ([@B76]). The authors suggest an indirect effect of *SBDS* mutation on energy production levels, indicating a possible role of calcium homeostasis in altering complex IV activity. In our lab we performed a characterization of a cellular model for SDS by immortalizing Mouse Embryonic Fibroblasts (MEFs; [@B12]) derived from an SDS mouse model carrying the R126T mutation in homozygosity (*Sbds^R126T/R126T^* MEFs) ([@B97]). Briefly, we established a model for studying SBDS function by retrasducing *Sbds^R126T/R126T^* MEFs with either wild-type *Sbds* (*Sbds^RESCUE^*), or mock control (*Sbds^MOCK^*) vectors. In this way, we can separate direct events due to a lack of SBDS from indirect effects. We confirmed a decrease in ATP levels associated with *Sbds* mutation. In addition, our RNA-Seq analysis revealed that genes belonging to complex IV were less expressed when *Sbds* was mutated (Figure [1](#F1){ref-type="fig"}). This downregulation could explain an impairment in cytochrome C oxidase activity and a consequent defect in ATP production. Moreover, there is a defect in oxygen consumption rate in SDS cells ([@B76]; [@B12]), as well as a reduction in the lactate/pyruvate ratio ([@B12]). The mechanistic connection between ribosome function and the metabolic effects of its impairment is still to be clarified. Overall, a reduction in ribosomal efficiency seems to associate with a reduction in energy levels and lipid biosynthesis. We suggest that ribosomal capability has coevolved with other cellular functions and, specifically, ribosomes are intimately linked to nutrient levels and cellular growth.

![Heat map representing relative gene expression levels in a cellular model for Shwachman Diamond Syndrome. We re-infected cells bearing the mutation R126T/R126T (corresponding to one of the most common mutations associated with Shwachman Diamond Syndrome) in the *Sbds* gene (*Sbds^R126T/R126T^* MEFs) with either wild type *Sbds* (*Sbds^RESCUE^*), or mock control (*Sbds^MOCK^*). Heat map represents relative gene expression levels of genes associated with mitochondrial electron transport chain complex IV, showing an overall reduction in *mutant Sbds^MOCK^* cells, indicating an impairment in ATP production. Heatmap is based on RNASeq raw data available at [www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress) with accession number ID [E-MTAB-5089](E-MTAB-5089), and analyzed in our previous work ([@B12]).](fgene-09-00533-g001){#F1}

The connection between ribosomes and growth is indeed strong and well-known. In *Drosophila melanogaster* the haploinsufficiency of RPs results in the *minute* phenotype, which includes short and thin bristles and smaller flies ([@B51]; [@B61]). Moreover, as shown by a myriad of papers, depletion of RPs causes a delay/arrest in cell cycle progression. In several cases, the regulation of growth is associated with ribosome independent function of RPs ([@B19]; [@B60], [@B27]; [@B113]). In other cases, the inhibition of growth has been directly linked to translational control driven by ribosomes ([@B6]). Depletion of different RPs may result in different types of inhibition of cell cycle progression, in line with the concept of heterogeneity in ribosomes ([@B5]). Conversely, nucleolar enlargement grossly equals an increased production of ribosomes and is observed in many cancers (Montanaro et al., 2008). In many models, some heterozygous deletions of RPs reduce tumor growth ([@B6]; [@B16]; [@B109]), while some others are associated with cancer development as demonstrated for the first time in zebrafish mutants for RPs in 2004 ([@B2]). In the last years, several somatic mutations have been linked to tumor progression and belong to both 60S subunits such as RPL5 (uL18) and RPL10 (uL16) ([@B22]), RPL 11 (uL5) ([@B101]; [@B29]), RPL22 (eL22) ([@B74]) and RPL 23 (uL23) ([@B29]) and to 40S subunits such as RPS15 (uS19) ([@B52]; [@B57]), RPS27 (eS27) ([@B28]) and RPSA (uS2) ([@B29]). On the contrary, RPs overexpression has been also identified in cancer progression ([@B4]; [@B39]; [@B112]). Several recent reviews provide a comprehensive discussion on how, in some cases, loss of RPs contributes to cancer ([@B94]; [@B35]; [@B72]).

The ribosomal apparatus also appears to affect longevity. Alterations in ribosomal protein expression result in an extension of eukaryotic lifespan ([@B40]; [@B90]).

In short, the persistent link between ribosomal function in growth and metabolism makes us speculate that there may be a yet-to-be-unveiled mechanistic connection. We favor a model in which mRNAs important for cell cycle progression or for key metabolic pathways contain UTRs that have coevolved with the translational machinery in order to be preferentially translated in conditions of optimal ribosomal capability. In this context, ribosomal heterogeneity may further tune the cell^′^s translational capabilities.

Mitochondrial Ribosomes
-----------------------

Several mitochondrial ribosome proteins are also involved in different cellular processes, such as cell cycle, apoptosis and mitochondrial homeostasis regulation. Mutations in mt-RPs genes are associated with mitochondrial dysfunctions and disorders ([@B82]; [@B88]; [@B83]; [@B62]; [@B77]). For instance, mutant *MRPS16 (bS16m)* causes mitochondrial respiratory chain disorders ([@B64]) and loss of *MRPL10 (uL10m)* diminished mitochondrial respiration and intracellular ATP levels ([@B55]). In addition, a recent study claims the regulation of cytoplasmic protein homeostasis by mitochondrial translation ([@B92]). These studies elucidate the fact that a crosstalk between the cytoplasmic and the mitochondrial ribosomal machinery may be present.

Conclusion
==========

Ribosomes have been long considered as monolithic structures ensuring mRNAs translation in a passive way. Nowadays, it has been well established that ribosomes can affect not only mRNA selection but also other fundamental processes such as cell growth and lately, cell homeostasis and metabolism (Figure [2](#F2){ref-type="fig"}). There is an increasing number of studies evidencing that the inter-correlation between ribosomes and metabolic pathways leads to a common cellular phenotype. Since ribosomes are a rate-limiting component of the translational program, further studies are needed to elucidate specific molecular mechanisms by which ribosome heterogeneity, supported by the translational apparatus, sustain cell growth and metabolic homeostasis.

![A schematic model representing the list of genes whose mutations perturb ribosome machinery. The color indicates the associated phenotype, specified in ovals in the third row. In some cases, the effect is associated or supposed to be associated with extra-ribosomal functions of mutated genes (listed in squares in the fourth row). Briefly, alterations in ribosome biogenesis and/or mutations in ribosomal proteins are responsible for metabolic changes, abnormal cell cycle progression/cell growth, and selective translation. Ribosomal subunits adapted from 40S ([@B58]) PDB code 5ANB to 60S ([@B108]) PDB code 4KZX. Orange color indicates the flux of alterations converging to metabolic defects, green color the flux converging to selective translation and blue color the one converging to altered cell cycle/cell growth. The exploration of effects of RP lesions on cell cycle, translation, and cell metabolism is a highly active area of research and novel effects of RP lesions still need to be discovered. ^1^[@B21]; ^2^[@B12]; ^3^[@B3]; ^4^[@B76]; ^5^[@B86]; ^6^[@B44]; ^7^[@B64]; ^8^[@B115]; ^9^[@B55]; ^10^[@B15]; ^11^[@B63]; ^12^[@B103]; ^13^[@B93]; ^14^[@B27]; ^15^[@B96]; ^16^[@B43]; ^17^[@B60]; ^18^[@B30]; ^19^[@B1]; ^20^[@B34]; ^21^[@B113]; ^22^[@B5]; ^23^[@B41]; ^24^[@B20]; ^25^[@B114]; ^26^[@B54]; ^27^[@B89]; ^28^[@B46]; ^29^[@B22].](fgene-09-00533-g002){#F2}
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